Treatment of human chronic fascioliasis with triclabendazole: Drug efficacy and serologic response
Author
dc.contributor.author
Apt Baruch, Werner
Author
dc.contributor.author
Aguilera,
Author
dc.contributor.author
Vega Vega, Luis Felipe
Author
dc.contributor.author
Miranda, Daniela
Author
dc.contributor.author
Zulantay Alfaro, Inés
Author
dc.contributor.author
Perez, Waldo
Author
dc.contributor.author
Gabor,
Author
dc.contributor.author
Admission date
dc.date.accessioned
2019-01-29T14:55:17Z
Available date
dc.date.available
2019-01-29T14:55:17Z
Publication date
dc.date.issued
1995
Cita de ítem
dc.identifier.citation
American Journal of Tropical Medicine and Hygiene, Volumen 52, Issue 6, 2018, Pages 532-535
Identifier
dc.identifier.issn
00029637
Identifier
dc.identifier.other
10.4269/ajtmh.1995.52.532
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/161326
Abstract
dc.description.abstract
Between November 1990 and March 1992, 24 asymptomatic individuals in Chile with chronic hepatic fascioliasis confirmed by the presence of Fasciola hepatica eggs in feces were treated with a single oral dose of trichlabendazole (10 mg/kg of body weight) after an overnight fast. Nineteen (79.2%) of 24 patients were egg-negative two months after treatment. Three of five cases with F. hepatica in feces after the first treatment were retreated and parasitologic cure was achieved. Tolerance to the drug was excellent; none of the patients had either secondary symptoms or important alterations in levels of aspartate and amino transferases, alkaline phosphatase, or bilirubin during or after treatment. Mild eosinophilia, present in 70% of the cases, persisted at least until 60 days after treatment. An enzyme-linked immunosorbent assay (ELISA) was highly effective in diagnosis and post- treatment monitoring. Before treatment, 20 (83.3%) of 24 confirmed cases had positive test results. The test re